OTTMUSG00000010552 Inhibitors
The chosen chemicals present a variety of indirect mechanisms aimed at inhibiting the protein PRAME like 30. These mechanisms are predicated on the hypothesis that by modulating specific cellular pathways and processes, these compounds possess the potential to indirectly impede the functional activities of PRAME like 30.
Two notable examples, Disulfiram and Vorinostat, illustrate the strategic approach of affecting metabolic and gene expression pathways, respectively. Disulfiram's ability to inhibit aldehyde dehydrogenase has the potential to result in the accumulation of metabolic intermediates. This accumulation, in turn, might exert an influence on the functional environment in which PRAME like 30 operates. On the other hand, Vorinostat, with its inhibitory activity against histone deacetylases, can bring about alterations in gene expression patterns. These alterations have the capacity to impact pathways associated with PRAME like 30, thereby potentially leading to its functional inhibition. These mechanisms represent intricate strategies to indirectly target PRAME like 30, and further experimental validation is warranted to ascertain their efficacy.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $52.00 $87.00 | 7 | |
Disulfiram, an aldehyde dehydrogenase inhibitor, can indirectly inhibit PRAME like 30 by disrupting aldehyde metabolism. This disruption could lead to altered cellular states that affect the activity of PRAME like 30, particularly in pathways related to oxidative stress and detoxification. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid, a histone deacetylase inhibitor, can affect chromatin remodeling and gene expression. This alteration in gene expression could indirectly inhibit PRAME like 30 by influencing the expression of genes involved in pathways where PRAME like 30 is functional. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, another histone deacetylase inhibitor, can modify gene expression patterns. This modulation could indirectly inhibit PRAME like 30 by affecting the transcription of genes in pathways related to PRAME like 30's function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, a proteasome inhibitor, impacts protein degradation pathways. This inhibition could indirectly affect PRAME like 30's function by altering the turnover of proteins involved in pathways where PRAME like 30 is active. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of cell growth and proliferation. This inhibition can indirectly affect PRAME like 30 by altering the cellular growth pathways in which PRAME like 30 might be involved. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059, a selective inhibitor of MEK, affects the MAPK/ERK pathway. By inhibiting MEK, PD 98059 could indirectly inhibit PRAME like 30 by disrupting signaling pathways where PRAME like 30 might play a role. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, affects the AKT signaling pathway. This pathway's inhibition could lead to indirect inhibition of PRAME like 30 by altering cell survival and growth processes where PRAME like 30 may be involved. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, another MEK inhibitor, targets the MAPK/ERK pathway. Inhibiting MEK1/2 can indirectly inhibit PRAME like 30 by affecting cell cycle regulation and differentiation processes potentially related to PRAME like 30's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAP kinase inhibitor, affects stress and inflammatory response pathways. Inhibiting p38 MAP kinase can indirectly inhibit PRAME like 30 by disrupting cellular stress responses where PRAME like 30 might be active. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, targets stress response and apoptosis pathways. Inhibition of JNK can indirectly affect PRAME like 30's function by altering the pathways involved in cellular stress responses and apoptosis. | ||||||